BioSpace News Archive

Precision BioSciences, Inc. (Nasdaq: DTIL) today announced completion of a strategic transaction with Imugene Limited (ASX: IMU) for global rights to Azercabtagene Zapreleucel (azer-cel), Precision’s lead allogeneic CAR T candidate, for cancer. Imugene will assume ongoing clinical execution for azer-cel in the large B-cell lymphoma (LBCL) population who have relapsed following autologous CAR T treatment.

Propanc Biopharma, Inc. today announced that the Company will target the Peter Mac Cancer Center in Melbourne, Australia, as the site for the First-In-Human (FIH) study for PRP in patients with advanced solid tumors.

ANGLE plc, a world-leading liquid biopsy company with innovative CTC diagnostic solutions for the research and diagnostic oncology market, will be releasing its interim results for the six months ended 30 June 2023 on Thursday 7 September 2023.

ValGenesis, Inc., the market leader in enterprise validation lifecycle management systems, and AUSTAR, a technology-based pharmaceutical engineering solutions provider, have partnered to deploy digital, risk-based solutions for life sciences companies in China.

BioCorRx Inc. (OTCQB: BICX) (the “Company”) today announced its submission to the US Food and Drug Administration (FDA) of an expanded access program application for BICX104 (implantable naltrexone pellet) for the treatment of opioid use disorder (OUD) patients that meet program eligibility criteria.

On August 14, 2023, Fuse Medical, Inc. (OTCPINK: FZMD) (“Fuse” or the “Company”) an emerging manufacturer and distributor of innovative medical devices for the orthopedic and spine marketplace, filed its quarterly report on Form 10-Q for the quarter ended June 30, 2023 with the Securities and Exchange Commission (“SEC”).

PathogenDx, a leader in next-generation microarray technology for better health and safety, announced the launch of QuantX Bacterial,

ArkX Laboratories, a leading provider of ultra far-field voice capture technology, will have its EveryWord™ Development Kit used as part of a research project on human communication in real life conducted by Uri Hasson, professor of psychology and neuroscience at Princeton University.

Curium, a world leader in nuclear medicine, announced today the positive results of the multi-center, open-label, Phase 2 SOLAR study of Copper Cu 64 PSMA I&T in patients with histologically-proven metastatic prostate cancer.

Global Coalition for Adaptive Research (LARKSPUR, CA) and Polaris Pharmaceuticals, Inc. (SAN DIEGO, CA), a subsidiary of Polaris Group (TWSE:6550)— The Global Coalition for Adaptive Research (GCAR) in collaboration with Polaris, today announced the activation of ADI-PEG 20 in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment – NCT03970447).